Zacks Investment Research Upgrades GENFIT S A/ADR (NASDAQ:GNFT) to Buy

GENFIT S A/ADR (NASDAQ:GNFT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Wednesday, Zacks.com reports. The brokerage presently has a $18.00 target price on the stock. Zacks Investment Research‘s target price indicates a potential upside of 20.64% from the stock’s current price.

According to Zacks, “Genfit SA is a biopharmaceutical company. It focuses on the discovery and development of therapeutic and diagnostic solutions in metabolic and liver related diseases. The company’s lead products include Elafibranor, Nitazoxanide and TGFTX1 which are in clinical stage. Genfit SA is based in Loos, France. “

A number of other equities analysts also recently issued reports on the stock. Roth Capital reiterated a “buy” rating on shares of GENFIT S A/ADR in a research note on Tuesday, April 23rd. Leerink Swann began coverage on shares of GENFIT S A/ADR in a research note on Wednesday, April 24th. They set an “outperform” rating and a $25.47 price objective on the stock. Svb Leerink began coverage on shares of GENFIT S A/ADR in a research note on Wednesday, April 24th. They set an “outperform” rating and a $58.00 price objective on the stock. HC Wainwright dropped their price objective on shares of GENFIT S A/ADR to $72.00 and set a “buy” rating on the stock in a research note on Monday, April 22nd. Finally, Stifel Nicolaus started coverage on shares of GENFIT S A/ADR in a research note on Tuesday, June 25th. They issued a “hold” rating for the company. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $45.69.

Shares of NASDAQ:GNFT opened at $14.92 on Wednesday. The stock’s 50 day moving average is $18.12. GENFIT S A/ADR has a one year low of $14.91 and a one year high of $26.25.

Several large investors have recently bought and sold shares of GNFT. Victory Capital Management Inc. acquired a new stake in GENFIT S A/ADR during the 1st quarter worth $2,358,000. Dean Capital Investments Management LLC acquired a new stake in GENFIT S A/ADR during the 1st quarter worth $650,000. TT International acquired a new stake in GENFIT S A/ADR during the 1st quarter worth $1,200,000. One68 Global Capital LLC acquired a new stake in GENFIT S A/ADR during the 1st quarter worth $270,000. Finally, Boussard & Gavaudan Investment Management LLP acquired a new stake in GENFIT S A/ADR during the 2nd quarter worth $199,000. Institutional investors and hedge funds own 14.69% of the company’s stock.

About GENFIT S A/ADR

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.

Recommended Story: How is an ETF different from a mutual fund?

Get a free copy of the Zacks research report on GENFIT S A/ADR (GNFT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GENFIT S A/ADR (NASDAQ:GNFT)

Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.